Abstract We evaluated clinical factors associated with symptomatic skeletal events (SSEs), radiographic progression-free survival (rPFS), and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with radium-223 (Ra-223). Of 101 enrolled patients, 93 were included in the final analysis (median follow-up, 25.2 months; interquartile range, 12.4–31.8). SSEs occurred in 26 patients (28.0%).
Masatoshi Eto
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Masatoshi
Contact Masatoshi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack